If you "don't understand the price action" why are you buying in here? Also, are you aware that the price of the stock will be reduced by any dividends MEMP declares between now and January 2017, so the distance to $10 may be longer than you think.
You guys never learn. It's not about the past it's about the future.They've not replaced their biggest customer (Rabobank) and that contract is almost completed.
Look up the word contango. You're constant buying more expensive futures contract to replace expiring futures contracts that have declined in value over the previous month. Therefore, if the price of oil stays the same, you are guaranteed to lose money. The only way these ETN's make sense is if you buy one day and correctly time a big spike the next day.
Keep your pants on. All the biotechs are in a "buy the rumor, sell the news" mode which was clearly predicable considering the pre-meeting run up.
This is not good news. The President and COO sold 1/3 of his position after last week's quarterly report. Yahoo will not let me post the link, but you can find it by going to the VDSI page on nasdaq.com, and click on "SEC filings" in the left column. When you're on the SEC filings page, it's the 2nd one listed (form type 4).
...and begging for an intelligent, non-sarcastic answer:
Why does the company seem to have difficulty cracking the US market? Is it because the US still uses the old magnetic strip credit cards while the rest of the world is moving to chip on a card? If so, once the US finally moves to chip on a card, it should be a bonanza for VDSI.
No specific target. There will be an early pop today and if it starts to fade I'll punch my ticket. I'm fortunate to have bought long ago in the single digits so I'm not going quibble on the exit price. I do admit I think this company will eventually be acquired so I'm concerned about missing that but I'm still inclined to take the money and run.
...a few warnings signs:
1. Dependence on single customer: "Revenues related to our delivery of all products sold to Rabobank globally exceeded 30% of the first quarter's revenue."
2. Forward guidance: "We expect that comparisons of 2015 results to the prior year will be stronger in the first half of this year than in the second half."
No, I am not short and have been long for ~ 5 years, but I will be looking for the exit door over the next few days.
Halozyme Therapeutics (HALO) Bullish Stance Reiterated at BMO Capital Amid Positive AACR Update
7:51 AM ET, 04/20/2015 - StreetInsider
BMO Capital analyst Jim Birchenough reiterated an Outperform rating and $26 price target on Halozyme Therapeutics (NASDAQ: HALO) after the American Association of Cancer Research meeting where, over the weekend, Halozyme PEGPH20 investigator, Dr. Sunil Hingorani discussed the targeting of hyaluronan (HA) in pancreatic cancer, noting that PEGPH20 combined with chemotherapy results in permanent favorable architectural changes after stoppage of PEGPH20.
Birchenough commented, "We maintain our Outperform rating on HALO following this weekend's AACR presentation and on prospects for PEGPH20 in pancreatic CA and other cancers with high HA expression. With impressive response rate and PFS data already established, we believe that enhanced biologic understanding of PEGPH20 action further increases confidence in prospects for success in pancreatic Ca. Durable benefit following early PEGPH20 termination and lasting effects on tumor vasculature could inform new dosing strategies to optimize therapeutic index across tumor types and realize the broad potential of PEGPH20 as a platform to enhance chemotherapy efficacy. We continue to see PEGPH20 as an undervalued asset, in the context of a HALO valuation that can be supported by partnered PH20 programs like HERCEPTIN SC and MABTHERA SC."
Actually your statement, "This move by management to offer to itself a special preferred stock with super voting rights, makes taking over board of VDSI virtually impossible" is incorrect, and should be amended to read, "This move by management to offer to itself a special preferred stock with super voting rights, makes taking over board of VDSI virtually impossible WITHOUT THE CONSENT OF THE BOARD". Everything is for sale at the right price. The CEO is 71 yo, owns 25% of the float, and should be ready to cash in his chips.
I rarely post but since there seems to be a new idiot on the board I felt the need to step up. Many of the company's officers exercised their options in March and, AS IS STANDARD OPERATING PROCDURE, sold a FRACTION of them to cover their tax liability, while holding on to the remainder.
So, if they knew margins would be under pressure they should not have said anything and left themselves open to a lawsuit?